Cantor Fitzgerald raised the firm’s price target on Cigna to $384 from $372 and keeps an Overweight rating on the shares. The firm came away from walked away Cigna’s 2024 Investor Day event incrementally more confident on its competitive positioning and is incrementally more convinced payors with high pharmacy benefit manager mix/low Medicare mix will be better-positioned stocks for 2024/2025, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on CI:
- Novo Nordisk (NYSE:NVO) Blasts Up on Weight Loss Drug News
- Cigna Corp Projects Growth and Hosts Investor Day
- Cigna backs FY24 adjusted EPS view at least $28.25, consensus $28.29
- Barclays starts health care facilities, managed care group with Neutral view
- Cigna Chairman Cordani sells over $6M in company shares
